Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial - Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; et al. (Lancet, 2023)